Professional paper

https://doi.org/10.15836/ccar.2014.563

Psoriasis, Cardiovascular Risk, and Antihypertensive Drugs

Saida Rezaković ; Policlinic “Eskulap” Zagreb, Croatia
Mima Georgieva ; Zabok General Hospital, Zabok, Croatia
Lidija Počanić ; Dubrava Clinical Hospital, Zagreb, Croatia

Abstract

Psoriasis is a chronic inflammatory disease affecting 1-2% of the adult general population. Disease is not limited only to the skin but is associated with a number of comorbidities, which significantly affect quality of life and present a higher risk of various medical disorders. Over recent years, numerous publications have shown increased frequency of cardiovascular disease and metabolic syndrome in patients with psoriasis. Although the etiopathogenetic relationship between these
conditions is still not entirely clear, it seems that they share common pathophysiological elements in terms of similar inflammatory components. Considering the increased prevalence of cardiovascular
comorbidities in patients, psoriasis should be approached as a multisystem disease. Therefore, a multidisciplinary approach is needed in order to most effectively manage patients with psoriasis. In addition, cardiac drugs have been frequently reported to induce or exacerbate psoriasis, among which beta-blockers are found to be the most common triggering drug. It is thus important to acknowledge this relationship, as this is cutaneous drug adverse reaction which significantly affects quality of life and is a great psychological burden and stigma for the patient, as well as having a great impact on further treatment compliance.

Keywords

cardiovascular risk; metabolic syndrome; comorbidities: beta-blockers, drug induced psoriasis

Hrčak ID:

139452

URI

https://hrcak.srce.hr/139452

Publication date:

20.1.2015.

Article data in other languages: croatian

Visits: 2.571 *